Interpretation of Key Points in 2024 Chinese Expert Consensus on EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer
10.3971/j.issn.1000-8578.2025.25.0120
- VernacularTitle:《EGFR 20外显子插入突变非小细胞肺癌中国专家共识（2024 版）》要点解读
- Author:
Xuanhong JIN
1
;
Fei ZHOU
2
Author Information
1. Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China.
2. Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
- Publication Type:GUIDELINESINTERPRETATION
- Keywords:
Non-small cell lung cancer;
EGFR exon 20 insertion;
Targeted therapy strategies
- From:
Cancer Research on Prevention and Treatment
2025;52(6):520-526
- CountryChina
- Language:Chinese
-
Abstract:
The Chinese Society of Clinical Oncology (CSCO) NSCLC Expert Committee has updated the 2023 Chinese expert consensus in light of the growing understanding of epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC) and the emergence of new clinical data from targeted therapies. Based on the latest domestic and international literature, clinical evidence, and expert experience, the “Chinese Expert Consensus on the Standardized Diagnosis and Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)” introduces refinements in the diagnostic and upcoming therapeutic strategies for this rare mutation. This article also highlights the key updates and recommendations in the 2024 consensus compared to the 2023 version as well as outlines future directions to optimize clinical practices and improve patient outcomes.
